Please assess the completion status of the following clinical trial:

Trial Title: Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years old~* COVID-19 positive on (RT-PCR) nasopharyngeal swab, or suspected COVID-19 infection with detectable SARS-CoV-2 IgG or IgM.~* Intensive care unit (ICU) patient or non-ICU patient on invasive mechanical ventilation, BiPAP, 100% non-rebreather mask, or high flow oxygen or supplemental oxygen of at least 4 liters per minute nasal cannula.~* D dimer level greater than 700 ng/mL (3 times the upper limit of normal).~Exclusion Criteria:~* Objectively documented deep vein thrombosis or pulmonary embolism~* Patients in whom there is very high suspicion for pulmonary embolism and are on full-dose anticoagulation as per the treating physician~* Platelets \<30,000 not due to disseminated intravascular coagulation (DIC), based on the International Society of Thrombosis and Haemostasis (ISTH) criteria and American Society of Hematology (ASH) Frequently Asked Questions~* Active bleeding that poses a contraindication to therapeutic anticoagulation in the opinion of the investigator.~* History of bleeding diathesis (e.g., hemophilia, severe von Willebrand disease, severe thrombocytopathy)~* History of intracranial hemorrhage in the last 90 days~* History of ischemic stroke in the past 2 weeks~* Major neurosurgical procedure in the past 30 days~* Cardiothoracic surgery in the past 30 days~* Intra-abdominal surgery in the past 30 days~* Intracranial malignancy~* Patients who require therapeutic anticoagulation for other reasons like atrial fibrillation, deep venous thrombosis, pulmonary embolism, or antiphospholipid syndrome.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intermediate Dose Prophylaxis (Type: ACTIVE_COMPARATOR): Subjects will receive one of the following interventions, at their physician's discretion:~* Enoxaparin 0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min~* Enoxaparin 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 mL/min~* If patient develops acute kidney injury: unfractionated heparin 7,500 units subcutaneously every 8 hours.~* Fondaparinux (if history of heparin-inducted thrombocytopenia \[HIT\]) 2.5 mg daily subcutaneously
- Therapeutic Dose Anticoagulation (Type: EXPERIMENTAL): Subjects will receive one of the following interventions, at their physician's discretion:~* Unfractionated heparin (UFH) to target anti-Xa level 0.3 -0.7 IU/mL or activated partial thromboplastin time (aPTT) (according to institutional protocol).~* Enoxaparin 1 mg/kg subcutaneously every 12 hours~* Argatroban (if heparin-induced thrombocytopenia \[HIT\]), dosed according to institutional protocol.~* Fondaparinux (if HIT and creatinine clearance greater than or equal to 50 ml/min) dosed by weight:~  * ≥100 kg: 10 mg daily~ * \<100 kg but ≥50 kg: 7.5 mg daily~ * \<50 kg: 5 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).